Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 nM) and recurrence, but no association with CYP2D6 was shown in the NSABP P1 and P2 prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: DeCensi, Andrea, Johansson, Harriet, Helland, Thomas, Puntoni, Matteo, Macis, Debora, Aristarco, Valentina, Caviglia, Silvia, Webber, Tania Buttiron, Briata, Irene Maria, D’Amico, Mauro, Serrano, Davide, Guerrieri-Gonzaga, Aliana, Bifulco, Ersilia, Hustad, Steinar, Søiland, Håvard, Boni, Luca, Bonanni, Bernardo, Mellgren, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994552/
https://www.ncbi.nlm.nih.gov/pubmed/33767162
http://dx.doi.org/10.1038/s41523-021-00236-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994552/
https://www.ncbi.nlm.nih.gov/pubmed/33767162
http://dx.doi.org/10.1038/s41523-021-00236-6

Ejemplares similares